ESPR
Esperion Therapeutics, Inc.Company Information
- Company Name
- Esperion Therapeutics, Inc.
- CIK
- CIK0001434868
- Category
- Accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ESPR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ESPR
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-06-17
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 266,110
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 181,470,018
- Shares outstanding
- 251,353,086
- Ownership
- 72.20%
Earnings Market Reaction
- Filing date
- 2026-05-08
- Price on filing date
- —
- 1-month reaction
- -0.32%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 156 | 168 | 92 | 86 | 115 | 145 | 145 | 189 | 227 | 82 | 115 | 138 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Accounts Receivable Net Current | 132 | 140 | 119 | 108 | 81 | 80 | 68 | 60 | 55 | 48 | 43 | 41 | ||||||
| Inventory Net | 104 | 105 | 109 | 114 | 99 | 94 | 80 | 84 | 73 | 66 | 51 | 46 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 4 | 4 | 5 | 5 | 4 | 14 | 11 | 11 | 5 | 6 | 4 | ||||||
| Assets Current | 459 | 463 | 360 | 343 | 319 | 338 | 308 | 345 | 366 | 201 | 218 | 232 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 3 | 4 | 5 | 6 | 6 | 7 | 7 | 5 | 3 | 2 | ||||||
| Intangible Assets Net Including Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 463 | 466 | 364 | 347 | 324 | 344 | 314 | 352 | 373 | 206 | 221 | 235 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 68 | 65 | 78 | 75 | 72 | 52 | 35 | 48 | 28 | 32 | 26 | 25 | ||||||
| Convertible Notes Payable Current | - | 0 | 55 | 55 | 55 | 55 | - | - | - | 0 | - | - | ||||||
| Other Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | 25 | - | - | ||||||
| Contract With Customer Liability Current | 44 | 34 | 31 | 22 | 5 | 9 | 15 | 21 | 29 | 25 | 20 | 16 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 1 | 1 | ||||||
| Liabilities Current | 300 | 301 | 359 | 299 | 271 | 246 | 166 | 175 | 165 | 156 | 138 | 107 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Convertible Long Term Notes Payable | 97 | 97 | 97 | 97 | 97 | 97 | 263 | 262 | 262 | 262 | 261 | 261 | ||||||
| Other Long Term Debt Noncurrent | 153 | 152 | 152 | 146 | 141 | 141 | - | - | - | 0 | - | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 4 | 4 | 3 | 2 | 2 | ||||||
| Other Liabilities Noncurrent | 9 | 9 | 7 | 7 | - | 0 | - | - | - | - | - | - | ||||||
| Liabilities | 770 | 768 | 815 | 781 | 750 | 733 | 684 | 697 | 667 | 661 | 631 | 607 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,396 | 1,376 | 1,289 | 1,275 | 1,270 | 1,267 | 1,264 | 1,261 | 1,249 | 1,149 | 1,138 | 1,135 | ||||||
| Treasury Stock Value | - | - | - | - | - | - | - | - | - | - | - | -55 | ||||||
| Treasury Stock Common Value | -55 | -55 | -55 | -55 | -55 | -55 | -55 | -55 | -55 | -55 | -55 | - | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | 0 | - | - | - | 0 | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -1,649 | -1,624 | -1,686 | -1,654 | -1,641 | -1,601 | -1,580 | -1,550 | -1,488 | -1,549 | -1,493 | -1,452 | ||||||
| Stockholders Equity | -308 | -302 | -451 | -434 | -426 | -389 | -370 | -344 | -294 | -455 | -410 | -372 | ||||||
| Liabilities And Stockholders Equity | 463 | 466 | 364 | 347 | 324 | 344 | 314 | 352 | 373 | 206 | 221 | 235 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 480 | 480 | 480 | 480 | 480 | 480 | 480 | 480 | 480 | 480 | 480 | 480 | ||||||
| Common Stock Shares Issued | 259 | 247 | 207 | 202 | 199 | 198 | 197 | 197 | 190 | 120 | 114 | 103 | ||||||
| Treasury Stock Common Shares | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEsperion Therapeutics, Inc. (ESPR) — SEC Financial Statements & Analysis
Esperion Therapeutics, Inc. (ESPR) is a pharmaceutical preparations company, incorporated in DE. Esperion Therapeutics, Inc. trades on Nasdaq as: ESPR. Esperion Therapeutics, Inc. (ESPR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-08. Based on that filing, On profitability, Esperion Therapeutics, Inc. posts a gross margin of 125.51%, an operating margin of 18.12%, a net margin of -1.77%, a Return on Equity (ROE) of 2.02%, and a Return on Assets (ROA) of -1.89%. Per share, it reports EPS of $-0.03, diluted EPS of $-0.03, free cash flow per share of $-0.07, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 61.13% year-over-year, net income growth of -95.16% year-over-year, and EPS growth of -96.22% year-over-year. On the balance sheet, it maintains a current ratio of 1.53x, a quick ratio of 1.16x, working capital of $159.10M, a debt-to-equity ratio of -2.50x, a debt ratio of 1.67, an interest coverage ratio of 0.89x, free cash flow of $-18.38M (TTM), and net debt of $-58.76M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-0.03
- ROE TTM
- 2.02%
- ROA TTM
- -1.89%
- Debt To Equity
- -2.50x
- Free Cash Flow TTM
- $-18.38M
- Net Revenue TTM Growth 1Y
- 61.13%
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Esperion Therapeutics, Inc. in?
Esperion Therapeutics, Inc. (ESPR) operates in the Pharmaceutical Preparations industry.
What exchange does ESPR trade on?
Esperion Therapeutics, Inc. (ESPR) trades on the Nasdaq.
Where is Esperion Therapeutics, Inc. incorporated?
Esperion Therapeutics, Inc. is incorporated in DE.
When was Esperion Therapeutics, Inc. (ESPR)'s most recent SEC filing?
Esperion Therapeutics, Inc. (ESPR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-08.
What is ESPR's EPS (earnings per share)?
Esperion Therapeutics, Inc. (ESPR)'s trailing twelve month EPS is $-0.03 as of 2026-03-31.
What is ESPR's ROE (return on equity)?
Esperion Therapeutics, Inc. (ESPR)'s trailing twelve month Return on Equity (ROE) is 2.02% as of 2026-03-31.
What is ESPR's ROA (return on assets)?
Esperion Therapeutics, Inc. (ESPR)'s trailing twelve month Return on Assets (ROA) is -1.89% as of 2026-03-31.